Oral administration of omipalisib, an investigational inhibitor of PI3K and mTOR cellular signals, can reduce the activity of pro-fibrotic cells…
Articles by Alice Melão, MSc
Evotec and Galapagos will work together to develop a strategy to target fibrosis affecting several organs, the companies…
Canada’s SQI Diagnostics and the University Health Network (UHN) will work together to advance the development and approval…
A new subtype of immune cells carrying a unique genetic profile was identified and found to have an important role…
Galapagos has started the worldwide ISABELA Phase 3 program to evaluate the potential of GLPG1690 as a treatment for…
Preclinical data show that treatment with Nuformix’s investigational candidates within the NXP002 program can prevent fibrosis progression with…
Middle-age adults with reduced respiratory function have up to a 27% higher risk of developing dementia or cognitive impairment later…
Reduced levels of decorin proteins in the blood may be linked to a lower risk of death among patients with…
A new small molecule inhibitor of the LOXL2 enzyme, developed by Pharmaxis, is safe and holds potential to treat…
A greater decline in lung function prior to treatment start may lead idiopathic pulmonary fibrosis (IPF) patients to stop using…